Rationale for Controlled Continuous Local Delivery of Sirolimus Through Porous ePTFE

  • Sirolimus (rapamycin) is an established FDA approved drug with a 20 year history of safety & efficacy

  • Sirolimus formulation is stable at body temp

  • Infusion can be adjusted, delayed or stopped

  • Systemic drug concentrations of sirolimus well below immunosuppressive levels

  • Ready antidote:  Stop or remove drug pump leaving a largely unaffected ePTFE graft